Molecular testing for mycoplasma genitalium in the United States: Results from the AMES prospective multicenter clinical study

Charlotte A. Gaydos, Lisa E. Manhart, Stephanie N. Taylor, Rebecca A. Lillis, Edward W. Hook, Jeffrey D. Klausner, Carmelle V. Remillard, Melissa Love, Byron McKinney, Damon K. Getman

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


A prospective multicenter clinical study involving subjects from 21 sites across the United States was conducted to validate the performance of a new in vitro diagnostic nucleic acid amplification test (NAAT) for the detection of Mycoplasma genitalium. Seven urogenital specimen types (n=11,556) obtained from 1,778 females, aged 15 to 74 years, and 1,583 males, aged 16 to 82 years, were tested with the Aptima Mycoplasma genitalium assay, an investigational transcription-mediated amplification (TMA) NAAT for the detection of M. genitalium 16S rRNA. Infected status for enrolled subjects was established using results obtained from testing either self-collected vaginal swab or clinician-collected male urethral swab specimens with a composite reference method consisting of three transcription-mediated amplification NAATs targeting unique regions of M. genitalium 16S or 23S rRNA. M. genitalium prevalence was 10.2% in females and 10.6% in males; prevalence was high in both symptomatic and asymptomatic subjects for both sexes. Compared to the subject infected status standard, the investigational test had sensitivity and specificity estimates, respectively, of 98.9% and 98.5% for subjectcollected vaginal swabs, 92.0% and 98.0% for clinician-collected vaginal swabs, 81.5% and 98.3% for endocervical swabs, 77.8% and 99.0% for female urine, and 98.2% and 99.6% for male urethral swabs, 88.4% and 97.8% for self-collected penile meatal swabs, and 90.9% and 99.4% for male urine specimens. For all seven specimen types, withinspecimen positive and negative agreements between the investigational test and the composite reference standard ranged from 94.2% to 98.3% and from 98.5 to 99.9%, respectively. These results provide clinical efficacy evidence for the first FDA-cleared NAAT for M. genitalium detection in the United States.

Original languageEnglish (US)
Article numbere01125-19
JournalJournal of clinical microbiology
Issue number11
StatePublished - 2019


  • Aptima
  • Aptima Mycoplasma genitalium Evaluation Study (AMES)
  • Mycoplasma genitalium
  • Sexually transmitted infection

ASJC Scopus subject areas

  • Microbiology (medical)


Dive into the research topics of 'Molecular testing for mycoplasma genitalium in the United States: Results from the AMES prospective multicenter clinical study'. Together they form a unique fingerprint.

Cite this